GTLB has given the market a lot to digest — a clean Q1 beat, a guidance raise, a 14% headcount cut, and a 5.8% pullback on the day analysts were lifting targets.
The most telling detail this week is what shorts have not done. Short interest barely moved after the Q1 print, slipping less than 1% on the day to 13.4% of the free float — and the one-week change is still a sharp 23% higher than where it was seven days ago. That means the majority of the pre-earnings build in short positioning remains intact. The stock is up 19% on the week and nearly a third over the past month, yet bears have not meaningfully covered. The standoff between a rallying price and sticky short interest is the central tension heading into the next catalyst.
The borrow market adds context but not pressure. Cost to borrow has risen 54% over the past week to 0.47%, roughly its highest level of recent months — but 0.47% is still objectively cheap. Availability remains extraordinarily loose at 1,685% of short interest, meaning there are roughly 17 shares available to borrow for every one already lent out. Borrow conditions give shorts no reason to panic-cover on cost alone. Options traders are similarly unmoved: the put/call ratio is 0.40, almost exactly in line with its 20-day average and nowhere near the 52-week high of 0.62. Neither the lending market nor the options market is signaling squeeze pressure — the positioning simply sits there, elevated, waiting.
The Street moved targets up but stayed in neutral. Across the board today, the firms that reacted to earnings raised their price targets — JP Morgan to $32 from $28, UBS to $32 from $24, Cantor Fitzgerald to $35 from $27 — yet every single one of them held their Neutral or equivalent rating. Morgan Stanley lifted to $30 from $29 and kept Equal-Weight. RBC and Mizuho followed the same pattern: higher targets, same cautious stance. The lone Buy on the tape is Rosenblatt at $43, which at a 35% premium to the current price of $31.82 stands well clear of the pack. The mean target is $33.43, marginally above where the stock closed — a picture of analysts who acknowledge the beat but aren't convinced the re-rating has further to run. On valuation, the P/E has expanded to 36.6x and price-to-book to 4.5x, both meaningfully higher than a month ago, and EV/EBITDA has drifted down to 26x as the earnings improvement works through. Factor scores are muted: EPS surprise ranks in only the 16th percentile and 90-day EPS momentum in the 12th, signalling the earnings beat hasn't yet shifted the forward estimate picture materially.
The institutional picture has its own subplot. The CEO, Bill Staples, made modest open-market purchases in late March — small in dollar terms but directionally constructive. Against that, founder and Executive Chairman Sytse Sijbrandij sold roughly $2.9 million of stock in May at prices around $24, well below where the stock trades now. Net insider activity over 90 days is positive at approximately $34 million, though the bulk of that figure appears driven by the Sijbrandij sales skewing the calculation in a counterintuitive direction. PRIMECAP built a new position of over 6 million shares as of Q1-end, and AQR added 3.2 million — two active managers stepping in while short sellers were building their own position tells a reasonably balanced ownership story.
What to watch: the next earnings date is June 17, two weeks away. The prior Q4 print produced a 4.4% one-day drop and an 11.5% five-day drop — making the current short interest level less puzzling, and making the Street's near-consensus "hold" posture the clearest frame for how the next two weeks unfold.
See the live data behind this article on ORTEX.
Open GTLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
